Market capitalization | $235.75m |
Enterprise Value | $343.11m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 2.49 |
P/S ratio (TTM) P/S ratio | 1.71 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 12.13% |
Revenue (TTM) Revenue | $137.74m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Heron Therapeutics Inc forecast:
4 Analysts have issued a Heron Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 138 138 |
12%
12%
|
|
Gross Profit | 99 99 |
81%
81%
|
|
EBITDA | -23 -23 |
80%
80%
|
EBIT (Operating Income) EBIT | -26 -26 |
79%
79%
|
Net Profit | -28 -28 |
77%
77%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Heron Therapeutics, Inc. is a biotechnology company, which engages in the development of pharmaceutical products for patients suffering from cancer. Its products portfolio include SUSTOL, Cinvanti, HTX-011, and HTX-034. The company was founded in February 1983 and is headquartered in Redwood City, CA.
Head office | United States |
CEO | Craig Collard |
Employees | 126 |
Founded | 1983 |
Website | www.herontx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.